Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1046 (116th)

Medicare Negotiation and Competitive Licensing Act of 2019

openUnited States· United States Congress· EN

Introduced

7 February 2019

Last action

25 September 2019 · Committee

Status

Subcommittee Hearings Held.

Sponsors

Rep. Doggett, Lloyd [D-TX-37], Sen. Welch, Peter [D-VT], Rep. Cummings, Elijah E. [D-MD-7], Rep. Adams, Alma S. [D-NC-12], Rep. Bass, Karen [D-CA-37], Rep. Beatty, Joyce [D-OH-3], Rep. Blumenauer, Earl [D-OR-3], Rep. Bonamici, Suzanne [D-OR-1], Rep. Cartwright, Matt [D-PA-17], Rep. Case, Ed [D-HI-1], Rep. Casten, Sean [D-IL-6], Rep. Castor, Kathy [D-FL-14], Rep. Castro, Joaquin [D-TX-20], Rep. Chu, Judy [D-CA-28], Rep. Cicilline, David N. [D-RI-1], Rep. Cisneros, Gilbert Ray [D-CA-31], Rep. Clay, Wm. Lacy [D-MO-1], Rep. Cleaver, Emanuel [D-MO-5], Rep. Cohen, Steve [D-TN-9], Rep. Courtney, Joe [D-CT-2], Rep. Crist, Charlie [D-FL-13], Rep. Crow, Jason [D-CO-6], Rep. Davis, Danny K. [D-IL-7], Rep. DeFazio, Peter A. [D-OR-4], Rep. DeLauro, Rosa L. [D-CT-3], Rep. DeSaulnier, Mark [D-CA-10], Rep. Dingell, Debbie [D-MI-6], Rep. Doyle, Michael F. [D-PA-14], Rep. Escobar, Veronica [D-TX-16], Rep. Espaillat, Adriano [D-NY-13], Rep. Evans, Dwight [D-PA-3], Rep. Frankel, Lois [D-FL-22], Sen. Gallego, Ruben [D-AZ], Rep. Garamendi, John [D-CA-8], Rep. Golden, Jared F. [D-ME-2], Rep. Gonzalez, Vicente [D-TX-34], Rep. Green, Al [D-TX-9], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Haaland, Debra A. [D-NM-1], Rep. Harder, Josh [D-CA-9], Rep. Hastings, Alcee L. [D-FL-20], Rep. Higgins, Brian [D-NY-26], Rep. Hill, Katie [D-CA-25], Rep. Jackson Lee, Sheila [D-TX-18], Rep. Jayapal, Pramila [D-WA-7], Rep. Johnson, Eddie Bernice [D-TX-30], Rep. Kaptur, Marcy [D-OH-9], Rep. Khanna, Ro [D-CA-17]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Summary

Medicare Negotiation and Competitive Licensing Act of 2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.) The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities. Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 7 February 2019

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 7 February 2019

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 7 February 2019

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  4. 7 February 2019

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 8 February 2019

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  6. 25 September 2019

    Committee

    Subcommittee Hearings Held.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 7 February 2019

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 7 February 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 7 February 2019

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 130 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.